Clinical Trials Logo

Clinical Trial Summary

This study aims to determine the effect of therapeutic hypothermia on reducing AKI in term and late-preterm infants with hypoxic ischemic encephalopathy as estimated by measurment of serum(s) neutrophil gelatinase-associated lipocalin(NGAL) and serum (s) cystatin-C.


Clinical Trial Description

The study will be conducted at the NICU of Mansoura University children's Hospital and regional General Hospital where brain cooling is not available.

Infants will be identified in the delivery room or the NICU based on a per-specified inclusion and exclusion criteria. The admitting physician will inform the study team upon admitting the infants to prepare for obtaining consent form.

When a patient is admitted and satisfies the inclusion criteria, one of the investigators or delegate will approach the parent(s). Patient identification will be done by admitting residents or the nurse practitioners. Parents will be approached by the residents or the nurse practitioners while the signature of the consent form in case of agreement will be obtained by one of the investigators who are not responsible about the care of the infant. Using language understandable to the parent(s), the study protocol will be described in detail outlining the procedure and describing any potential risks. All parents will be specifically informed that a decision not to participate in the research study will in no way compromise their child's care. If the parent(s) agree that their child participate in the study, written informed consent will be obtained. A copy of the consent form will be kept with the investigators.

Infants will be classified into two groups, either group 1 (Cooled group) or group 2 (Non-cooled group) who missed opportunity to be identified within proper time.Categorization will be center-based according to the feasibility of cooling devices at proper time (the first 12 hours of the baby's life).

Group 1 (Cooled group) Cooling procedure We will fit a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. The system consists of a small thermostatically controlled cooling unit with a pump that circulated water through the cap. The initial water temperature is set between 8°C and 12°C. All infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. Adjustments will be made to the cooling cap water temperature to stay within these limits. At the start of hypothermia, the overhead heater will be turned off for 20-30 min to accelerate cooling, and then turned back on once the rectal temperature had fallen to 35.5ºC.

Rewarming procedure At the end of the 72 h cooling period, the infants will slowly rewarmed at no more than 0.5ºC /h until their temperature was within normal temperature range (36.5-37.5ºC). The overhead heater can be adjusted as needed, to rewarm the infant. The infant's temperature will be be carefully monitored for at least 4 hours to prevent rebound hyperthermia, as this might be detrimental.

Group 2 (Non-cooled group):

Infants in the non-cooled group received the standard of care and will placed under radiant heaters or in incubators, which will be servo-controlled according to the abdominal skin temperature to maintain the rectal temperature at 37.0± 0.2°C.

Laboratory test results Serum creatinine, electrolyte levels, and liver function tests will be assessed before the start of cooling (baseline); at 72 during cooling; and then on days and 10 of life as clinically indicated. Blood sample for sNGAL and cystatine C will be obtained at Day 1, 4 and 10 of life.

Statistical Analysis Statistical analysis will be performed using SPSS statistical software (version 16; SPSS, Chicago, Illinois). Student-t test or Mann-Whitney test will be used to compare continuous variables and Chi-square test or Fisher's exact test will be used for categorical variables. The diagnostic accuracy of the sNGAL and cystatine C tested in this study for identifying AKI will be evaluated by constructing receiver operating characteristics (ROC) curves. A p-value of <0.05 is considered to be statistically significant. All data will be expressed as mean ± standard deviation unless otherwise stated. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02683915
Study type Observational
Source Mansoura University Children Hospital
Contact
Status Completed
Phase
Start date September 2015
Completion date September 2016

See also
  Status Clinical Trial Phase
Withdrawn NCT02551003 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Recruiting NCT01962233 - Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy Phase 1
Completed NCT01683383 - California Transport Cooling Trial N/A
Completed NCT01471015 - Darbe Administration in Newborns Undergoing Cooling for Encephalopathy Phase 1/Phase 2
Completed NCT01649648 - Autologous Cord Blood Cells for Brain Injury in Term Newborns Phase 1
Completed NCT01481207 - Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy
Withdrawn NCT00993564 - Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE) N/A
Completed NCT00945789 - Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE) Phase 1/Phase 2
Completed NCT00097097 - Neonatal Resuscitation in Zambia Phase 3
Recruiting NCT02621944 - Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia Early Phase 1
Not yet recruiting NCT02605018 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Withdrawn NCT01128673 - MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE) N/A
Completed NCT01732146 - Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy Phase 3
Completed NCT02349672 - Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
Completed NCT02826941 - Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy Phase 2
Active, not recruiting NCT01138176 - Whole Body Cooling Using Phase Changing Material Phase 1/Phase 2
Recruiting NCT02578823 - Targeted Temperature Management After In-Hospital Cardiac Arrest N/A
Terminated NCT01765218 - Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy Phase 1/Phase 2
Completed NCT01241019 - Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia Phase 2
Completed NCT00620711 - Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy Phase 1